• Madrigal Pharmaceuticals recently reported that its MASH drug Rezdiffra generated nearly US$1.00 billion in its first full year on the market, reinforcing the company’s leading position in this disease area.
• This rapid commercial traction, coupled with management’s expectation for continued robust net sales growth in 2026, has attracted heightened attention from both institutional investors and short-sellers.
• Next, we’ll examine how Rezdiffra’s nearly US$1.00 billion first-year sales performance reshapes Madrigal’s investment narrative and future growth assumptions.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Madrigal Pharmaceuticals Investment Narrative Recap

To own Madrigal today, you need to believe Rezdiffra can anchor a durable MASH franchise despite reliance on a single asset and rising competition. The nearly US$1.00 billion first year of Rezdiffra sales supports the bull case that the launch is gaining real traction, but it does not remove the near term risk that future F4c data, payer pushback, or pricing pressure could challenge both the growth story and Madrigal’s margin outlook.

The most relevant recent announcement here is Madrigal’s full year 2025 earnings, which showed US$958.4 million in revenue but a net loss of US$288.3 million. That combination of strong top line and continued losses underlines why the next phase of the Rezdiffra launch, including any shift in gross to net discounts and ongoing SG&A spend, remains such a key catalyst for sentiment around the stock.

But against this strong first year, investors should still be aware of how quickly payer scrutiny or future safety and efficacy questions could...

Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028. This requires 68.6% yearly revenue growth and roughly a $1.1 billion earnings increase from -$281.9 million today.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $671.07 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Before this update, the most cautious analysts were already assuming revenue could reach about US$2.0 billion with earnings near US$402.6 million, yet they still flagged issues like European pricing pressure as reasons the market might be too optimistic, so this new sales milestone may prompt both them and you to reassess what outcomes really feel achievable.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth just $460.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.